BeiGene Ltd.
(NASDAQ : BGNE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.41%430.050.0%$6120.58m
BNTXBioNTech SE -3.62%359.180.0%$1251.77m
NVAXNovavax, Inc. 0.11%237.5479.4%$944.01m
SNSSSunesis Pharmaceuticals, Inc. 2.23%8.710.7%$608.86m
AMGNAmgen, Inc. 0.93%219.381.4%$559.38m
REGNRegeneron Pharmaceuticals, Inc. -0.20%651.882.7%$494.43m
GILDGilead Sciences, Inc. 0.39%71.611.0%$434.34m
ILMNIllumina, Inc. -0.65%447.013.5%$405.38m
TECHBio-Techne Corp. 0.92%534.354.5%$355.95m
BIIBBiogen, Inc. 0.17%300.191.7%$306.30m
VRTXVertex Pharmaceuticals, Inc. 0.64%188.301.9%$241.59m
ISEEIVERIC bio, Inc. 1.59%16.620.0%$194.78m
BGNEBeiGene Ltd. 4.65%403.141.3%$186.17m
LIFEaTyr Pharma, Inc. 0.49%10.313.2%$144.19m
EXASEXACT Sciences Corp. 5.22%108.1518.1%$135.69m

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.